{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:16:45Z","timestamp":1773281805442,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Horus Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13318-023-00853-5","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:02:35Z","timestamp":1694174555000},"page":"633-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations"],"prefix":"10.1007","volume":"48","author":[{"given":"Laure","family":"Chauchat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Kaluzhny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"2","key":"853_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2020.21899","volume":"325","author":"JD Stein","year":"2021","unstructured":"Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. JAMA. 2021;325(2):164\u201374.","journal-title":"JAMA"},{"key":"853_CR2","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th edn. Br J Ophthalmol. 2021;105(Suppl 1):1\u2013169.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"issue":"2\u20133","key":"853_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/jop.2013.0179","volume":"30","author":"NS Winkler","year":"2014","unstructured":"Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2\u20133):102\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"853_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/13816810.2016.1164193","volume":"38","author":"LP Doucette","year":"2017","unstructured":"Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthal Genet. 2017;38(2):108\u201316.","journal-title":"Ophthal Genet"},{"issue":"1","key":"853_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.6.1.45","volume":"6","author":"G Holl\u00f3","year":"2007","unstructured":"Holl\u00f3 G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45\u201352.","journal-title":"Expert Opin Drug Saf"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"1067942","DOI":"10.3389\/ftox.2023.1067942","volume":"5","author":"R Ruiz-Lozano","year":"2023","unstructured":"Ruiz-Lozano R, Azar N, Mousa H, Quiroga-Garza M, Komai S, Wheelock-Gutierrez L, et\u00a0al. Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy. Front Toxicol. 2023;5:1067942.\u00a0https:\/\/doi.org\/10.3389\/ftox.2023.1067942.","journal-title":"Front Toxicol"},{"issue":"4","key":"853_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0952-3278(94)90139-2","volume":"50","author":"S Basu","year":"1994","unstructured":"Basu S, Sj\u00f6quist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;50(4):161\u20138.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"7","key":"853_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/pharmaceutics11070321","volume":"11","author":"RV Moiseev","year":"2019","unstructured":"Moiseev RV, Morrison PWJ, Steele F, Khutoryanskiy VV. Penetration enhancers in ocular drug delivery. Pharmaceutics. 2019;11(7):321.","journal-title":"Pharmaceutics"},{"issue":"1","key":"853_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40265-017-0843-9","volume":"78","author":"G Holl\u00f3","year":"2018","unstructured":"Holl\u00f3 G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin\/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78(1):39\u201364.","journal-title":"Drugs"},{"issue":"1","key":"853_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/ICO.0b013e3181a3c3e6","volume":"29","author":"M Kusano","year":"2010","unstructured":"Kusano M, Uematsu M, Kumagami T, Sasaki H, Kitaoka T. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea. 2010;29(1):80\u20135.","journal-title":"Cornea"},{"issue":"4","key":"853_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"853_CR12","first-page":"40","volume":"110","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40\u201363.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"853_CR13","first-page":"1967","volume":"8","author":"A Alm","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol Auckl NZ. 2014;8:1967\u201385.","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"2","key":"853_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0181-5512(04)96106-2","volume":"27","author":"F Chiambaretta","year":"2004","unstructured":"Chiambaretta F, Pouliquen P, Menerath JM, Pilotaz F, Rebika H, Rigal D. Efficacy and safety of a fluid carbomer gel versus a conventional carbomer gel in dry eye treatment. J Fr Ophtalmol. 2004;27(2):130\u20135.","journal-title":"J Fr Ophtalmol"},{"key":"853_CR15","unstructured":"Organization for Economic Co-operation and Development (OECD), ENV\/MC\/CHEM(98)17, OECD series on principles of good laboratory practice and compliance monitoring No. 1, OECD Principles on Good Laboratory Practice (as revised in 1997) (1999) OECD principles of good laboratory practice (OECD, Principles of GLP, 1999). https:\/\/read.oecd-ilibrary.org\/environment\/oecd-principles-on-good-laboratory-practice_9789264078536-en#page1. Accessed 5 Sept 2023."},{"key":"853_CR16","unstructured":"Bundesgesetzblatt (BGBI). Gesetz zum Schutz vor gef\u00e4hrlichen Stoffen (Chemikaliengesetz-ChemG), 2013."},{"issue":"7","key":"853_CR17","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1167\/iovs.18-23944","volume":"59","author":"Y Kaluzhny","year":"2018","unstructured":"Kaluzhny Y, Kinuthia MW, Truong T, Lapointe AM, Hayden P, Klausner M. New human organotypic corneal tissue model for ophthalmic drug delivery studies. Invest Ophthalmol Vis Sci. 2018;59(7):2880\u201398.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"853_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11626-020-00533-7","volume":"57","author":"Y Kaluzhny","year":"2021","unstructured":"Kaluzhny Y, Klausner M. In vitro reconstructed 3D corneal tissue models for ocular toxicology and ophthalmic drug development. In Vitro Cell Dev Biol Anim. 2021;57(2):207\u201337.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"853_CR19","unstructured":"Gremilogianni AM, Kaluzhny Y, Tsoli C, Pantazopoulou S, Kinuthia M. Permeation of latanoprost eye drop formulations in epicorneal. Mat Tek Life Sci\u2014Soc Toxicol 2016 Annu Meet New Orleans, USA, 2016."},{"issue":"3","key":"853_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/jop.2017.0091","volume":"34","author":"Y Sekine","year":"2018","unstructured":"Sekine Y, Shimada M, Satake S, Okubo M, Hisaka A, Hara T, et\u00a0al. Pharmacokinetic analysis of intraocular penetration of latanoprost solutions with different preservatives in human eyes. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2018;34(3):280\u20136.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"7","key":"853_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/02713683.2020.1855660","volume":"46","author":"A Halder","year":"2021","unstructured":"Halder A, Khopade AJ. Pharmacokinetics and pharmacology of latanoprost 0.005% without benzalkonium chloride vs latanoprost 0.005% with benzalkonium chloride in New Zealand white rabbits and beagles. Curr Eye Res. 2021;46(7):1031\u20137.","journal-title":"Curr Eye Res"},{"key":"853_CR22","unstructured":"EMA. Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches, 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf. Accessed 5 Sept 2023."},{"issue":"1","key":"853_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/jop.2014.0015","volume":"31","author":"M Fukuda","year":"2015","unstructured":"Fukuda M, Sasaki H. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2015;31(1):57\u201360.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"7","key":"853_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/jop.2019.0102","volume":"36","author":"T Zhou","year":"2020","unstructured":"Zhou T, Miao Y, Li Z, Lu P, Liang Z, Yang J, et\u00a0al. A comparative ocular pharmacokinetics study of preservative-free latanoprost unit-dose eye drops and a benzalkonium chloride-preserved branded product following topical application to rabbits. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2020;36(7):522\u20138.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"2","key":"853_CR25","first-page":"127","volume":"118","author":"D Romaniuk","year":"2016","unstructured":"Romaniuk D, Smagur J, Cisek A, Antonik J, Romaniuk W. Does preservative content affect drug permeability? The permeability analysis in vitro of 3 ophthalmic Latanoprost formulations in a human epithelial cell culture model. Klin Oczna. 2016;118(2):127\u201332.","journal-title":"Klin Oczna"},{"issue":"1\u20132","key":"853_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2011.03.006","volume":"410","author":"A Ochiai","year":"2011","unstructured":"Ochiai A, Danjo K. The stabilization mechanism of latanoprost. Int J Pharm. 2011;410(1\u20132):23\u201330.","journal-title":"Int J Pharm"},{"issue":"10","key":"853_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/bjo.82.10.1131","volume":"82","author":"CG Wilson","year":"1998","unstructured":"Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC. Ocular contact time of a carbomer gel (GelTears) in humans. Br J Ophthalmol. 1998;82(10):1131\u20134.","journal-title":"Br J Ophthalmol"},{"key":"853_CR28","unstructured":"Mercier F, inventor; Laboratoires Th\u00e9a, assignee. Polymeric system for delivering a preservative-free prostaglandin-based nonviscous solution. European patent EP 2588078B1, 2014."},{"key":"853_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120924","volume":"607","author":"M Mofidfar","year":"2021","unstructured":"Mofidfar M, Abdi B, Ahadian S, Mostafavi E, Desai TA, Abbasi F, et\u00a0al. Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies. Int J Pharm. 2021;607: 120924.","journal-title":"Int J Pharm"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00853-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:29:01Z","timestamp":1699036141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00853-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00853-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"20 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laure Chauchat and Camille Guerin contributed to study conception, design, and result discussion, and article outlines. All authors reviewed and approved the manuscript. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published. The study was sponsored by Horus Pharma (Nice, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Laure Chauchat was employed by Horus Pharma Company. Camille Guerin was employed by Horus Pharma Company. Yulia Kaluzhny was employed by MatTek Life Sciences, a manufacturer of the EpiCorneal tissue model used in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"<i>In\u00a0vitro<\/i> experiments were performed on the basis of OECD Guidelines for Testing of Chemicals and the German \u201cBundesgesetzblatt (BGBI) Chemikaliengesetz\u201d (ChemG, 2013). Animal experiments were performed in accordance with the OECD Principles on good laboratory practice (GLP) and applicable facility Standard Operating Procedures (SOPs), Food and Drug Administration (FDA) and European Medicines Agency (EMA) requirement. All animals were treated according to the Directive 2010\/63\/UE European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes and to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. The registration number with the French Ministry of Research is #12827. This DAP (ethical project authorization request) was authorized by the Ministry on 8 January 2018 (and valid for 5\u00a0years). The ethics committee that approved this project is CEEA-087.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This work has been previously presented at the ARVO Annual Meeting, May 1\u20134, Denver, CO, 2022.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}